Japan's deepening political woes cloud budget, rate hike timing
TOKYO (Reuters) -Japan's deepening political uncertainty risks prolonging policy paralysis that could affect the drafting of next year's budget and the timing of the central bank's next interest rate hike, analysts say, clouding the outlook for the fragile economy.
Prime Minister Shigeru Ishiba is facing increased calls from within his ruling Liberal Democratic Party (LDP) to step down and take responsibility for the party's huge defeat in an upper house election in July and a lower house poll last year.
While Ishiba has denied he has any plans to resign, his fading support has triggered inevitable questions about his political future and analysts say a leadership change would likely have implications for the outlook for fiscal and monetary policy.
In a meeting on Friday, lawmakers decided to consider holding a rare leadership race even with the party head Ishiba still presiding. Under LDP rules, such a race would take place if the majority of the party's lawmakers and regional heads agreed to hold one.
But it is uncertain how long it would take for the party to decide, according to lawmakers and government officials familiar with the procedure told Reuters.
That contest could happen in September at the earliest, they say, which would allow the new administration to compile a spending package to cushion the economic blow from U.S. tariffs.
But if the race does not take place in September, it may have to wait until early next year to avoid disrupting the government's drafting of next fiscal year's budget, they say.
"We would not be surprised if the LDP calls for a leadership election in September," UBS analysts said in a research note. "It seems that uncertainties regarding politics are unlikely to resolve soon."
In Japan, the Ministry of Finance collects spending requests from ministries in August and finalises the government's draft budget in late December. The budget must pass parliament in time to take effect from the April start of a new fiscal year.
Failure to pass the budget through parliament would force the government to compile a stop-gap budget, which could hurt the economy by causing delays in expenditure.
Some ruling party lawmakers say there is no choice but for Ishiba to step down to resolve the deadlock.
Having lost control in both houses of parliament, the LDP-led ruling coalition needs opposition party support to pass legislation and budget through parliament. Opposition parties have ruled out forming a coalition unless Ishiba steps down.
"Japan needs a stable coalition government. Otherwise, it's impossible to pursue consistent policies," LDP heavyweight Ken Saito told Reuters last week. "It's best for the LDP to seek a coalition partner under a new leader."
COMPLICATION FOR BOJ
Ishiba's weak political standing and prolonged political uncertainty also complicate the Bank of Japan's decision on how soon to resume interest rate hikes.
While few analysts expect the BOJ to hike rates at its next policy meeting in September, some see a good chance of action in October, December or January next year when more data becomes available on the impact of U.S. tariffs on the economy.
Known as a fiscal hawk, Ishiba has endorsed the central bank's efforts to gradually wean the economy off a decade-long, massive stimulus as inflation remains above its 2% target for well over three years.
But his bitter election defeat has made his administration vulnerable to calls for big spending and loose monetary policy.
Many opposition parties have urged the BOJ to hold off, or go slow, in raising rates and focus on supporting the economy.
If the LDP were to hold a leadership race, the event could put the spotlight on the views of candidates like Sanae Takaichi, a reflationist-minded lawmaker who in the past blasted the idea of interest rate hikes as "stupid."
All this could discourage the BOJ from raising rates in coming months to avoid drawing unwanted political attention.
"All we can say is that we would continue to take appropriate policies to sustainably and stably achieve our 2% inflation target," Governor Kazuo Ueda told a news briefing earlier this month, when asked how the BOJ would respond if political changes lead to fresh demands on monetary policy.
"It's impossible to predict how politics will unfold, which means for the BOJ it's best to take a wait-and-see stance," said a source familiar with the bank's thinking.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
Wall St futures steady, chip stocks slip on China sales deal
(Reuters) -U.S. stock index futures were little changed on Monday as investors geared up for a busy week, while major chip companies seemed caught in the middle of the latest twist in trade policy ahead of a key tariff deadline with China. Semiconductor giant Nvidia dropped 1% in premarket trading and Advanced Micro Devices lost 2%. A U.S. official told Reuters that the companies had agreed to give the United States government 15% of revenue from the sales of their advanced computer chips to China, days after the Commerce Department began issuing licenses for the sale of Nvidia's H20 chips. Sale of the semiconductors was an integral issue in the U.S. agreement with China signed earlier this year and could strain the relationship between the two economies just before Tuesday's deadline for the deal's expiration. "The Trump administration reckons higher prices and snarled-up supply chains are an acceptable price to pay to encourage more U.S. manufacturing," said Susannah Streeter, head of money and markets, Hargreaves Lansdown. "The unusual arrangement is another example of a mega tech company acquiescing to the U.S. administration's demands, to gain an upper hand as trade relations are redrawn." Markets also await clarity on the sector tariffs U.S. President Donald Trump has announced. At 05:45 a.m. ET, Dow E-minis were up 98 points, or 0.22%, with 7,922 contracts changing hands, S&P 500 E-minis were up 6.25 points, or 0.10%, and Nasdaq 100 E-minis were up 11.5 points, or 0.05%. Traders took breather after last week's rally helped the S&P 500 and the Nasdaq log their strongest weekly performance in more than a month. Investors expect the recent shake-up at the U.S. Federal Reserve and signs of labor market weakness could nudge the central bank into adopting a dovish monetary policy stance later this year, fueling much of the optimism. Tuesday's consumer inflation report will either cast more doubt or offer clarity for investors, who are currently anticipating the Fed will lower borrowing costs by about 60 basis points by December, according to data compiled by LSEG. A better-than-feared earnings season was also a relief and BofA's monthly fund manager survey showed that owning megacap stocks was once again the most popular trade. Apple was a standout last week following its biggest weekly showing in five years, after the iPhone maker unveiled a series of U.S. investment pledges. The company's shares were down 0.7% on Monday. Gene therapy developers fell, with Sarepta Therapeutics dropping 7.6% and Capricor Therapeutics declined 9% as Vinay Prasad, a fierce critic of U.S. COVID-19 vaccine and mask mandates, was expected to return to the Food and Drug Administration. Intel was up 1.6% and focus turned to a report that said CEO Lip-Bu Tan was expected to visit the White House after Trump called for his removal last week. In geopolitical news, Trump and Russia's President Vladimir Putin are expected to meet on Friday to try and negotiate an end to the Ukraine war, which could also affect the outlook for crude prices. [O/R]
Yahoo
2 minutes ago
- Yahoo
Merifund Capital Management Projects AI Growth in AMD
AMD's Q2 earnings miss overshadowed by strong AI roadmap, record revenue growth, and expanding partnerships with global hyperscalers SINGAPORE, SG / / August 11, 2025 / Merifund Capital Management notes that AMD's latest quarterly results highlight a critical juncture for the semiconductor industry, with the company balancing significant top-line growth against intensifying regulatory constraints. Revenue in the second quarter reaches USD 7.35 billion, representing a 32% year-over-year increase, yet adjusted earnings per share of USD 0.46 fall slightly short of consensus expectations of USD 0.47-0.49. Market reaction sees shares decline by approximately 6%, reflecting investor caution over export restrictions and earnings pressure. U.S. government measures introduced in April 2025 targeting AMD's MI308 data-centre GPUs effectively remove access to the Chinese market, resulting in an estimated USD 763.37 million in inventory and related charges for the quarter. Without these charges, AMD's non-GAAP gross margin would be close to 54%, compared with the reported 43.3%. Merifund Capital Management's analysis underscores that the company's accelerated transition to its next-generation GPU portfolio may provide a structural advantage as hyperscalers seek alternative suppliers. Segment performance presents a mixed picture. Data-centre revenue increases 14.3% year-over-year to USD 3.09 billion, client revenue rises 67.5% to USD 2.39 billion, and gaming revenue grows 73.2% to USD 1.07 billion, while the embedded segment declines 4.3% to USD 786.27 million. The strong performance in multiple business lines reinforces Merifund's view that AMD retains operational resilience despite geopolitical headwinds. The launch of the Instinct MI350 series this year delivers fourfold generation-on-generation AI compute gains and incorporates 288 GB of HBM3E memory with bandwidth reaching 8 TB/s. AMD's preview of its MI400 series for 2026 introduces a leap to 432 GB of HBM4 with 19.6 TB/s bandwidth, more than doubling memory capacity. Merifund's report highlights that this product trajectory positions AMD as a credible challenger in the high-performance AI accelerator space. Partnerships with OpenAI, Meta, and Microsoft support this assessment. OpenAI intends to deploy the MI350 series in production workloads, Meta is integrating MI300X GPUs into Llama 3 and Llama 4 inference, and Microsoft is making MI300X available through Azure. While Nvidia retains an estimated 85-92% market share, AMD's current position in the 8-14.3% range demonstrates its growing foothold. The total addressable market for AI accelerators is projected to exceed USD 477.11 billion by 2028. Merifund Capital Management estimates that even a 5% market share could push AMD's earnings per share above USD 8.59 within three years. The company's open ecosystem approach through the ROCm software stack is a differentiator, offering hyperscalers supply-chain diversification while optimising cost-to-performance metrics. Merifund Capital Management maintains that AMD's execution on its AI roadmap, coupled with strategic industry partnerships, provides clear visibility into scaling opportunities. The firm's view is that while quarterly results face near-term challenges, the long-term growth engine remains robust. About Merifund Capital Management Founded in 2010, Merifund Capital Management Pte. Ltd. (UEN: 201024554E) is a Singapore-headquartered hedge-fund management firm specialising in ESG-integrated investment strategies across traditional long-only asset and portfolio management, long/short equity, global macro, event-driven, and systematic trading. The firm strategically employs derivatives to optimise market opportunities while emphasising capital preservation, liquidity, and disciplined risk controls. Merifund serves accredited investors, family offices, foundations, and endowments, and is expanding its offering to retail investors. For additional information, visit or contact Tao Yang at media@ Media Contact: Contact Person: Tao Yang Company: Merifund Capital Management Pte. Ltd. Email: media@ Website: SOURCE: Merifund Capital Management View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 minutes ago
- Yahoo
Asia-Pacific Molecular Oncology Diagnostics Market Research 2024-2033
The Asia-Pacific molecular oncology diagnostics market, valued at $513.6 million in 2024, is projected to surge to $1.54 billion by 2033 with a CAGR of 12.99%. Key technologies like digital PCR, liquid biopsy, and next-generation sequencing are driving growth amid rising cancer rates in China, India, and Japan. While high costs and a shortage of skilled professionals challenge expansion, collaborations and innovations are enhancing molecular diagnostic adoption. Strategic efforts, including AI, reimbursement standardization, and genomic literacy programs, aim to advance precision oncology in the APAC region, addressing barriers and harnessing growth opportunities. Asia-Pacific Molecular Oncology Diagnostics Market Dublin, Aug. 11, 2025 (GLOBE NEWSWIRE) -- The "Asia-Pacific Molecular Oncology Diagnostics Market: Focus on Cancer Type, End User, and Country - Analysis and Forecast, 2024-2033" has been added to Asia-Pacific molecular oncology diagnostics market was valued at $513.6 million in 2024, and the market is expected to grow with a CAGR of 12.99% and reach $1.54 billion by 2033. Digital PCR, liquid biopsy, and next-generation sequencing (NGS) are the main technological factors propelling the APAC molecular cancer diagnostics market's explosive expansion. The need for earlier detection, more accurate therapy choices, and ultimately improved patient outcomes is being fuelled by the rising incidence of cancer in nations like China, India, and Japan. The market for molecular oncology diagnostics in Asia-Pacific (APAC) is expected to grow quickly as healthcare systems in China, India, Japan, and Southeast Asia place a greater emphasis on precision medicine. The use of molecular assays, especially next-generation sequencing (NGS), digital PCR, and liquid biopsy, is growing because they can more precisely and early identify genetic changes linked to cancer than conventional techniques. The demand for these cutting-edge instruments is being driven by the rising prevalence of colorectal, lung, and breast cancers as well as increased patient and physician awareness. Clinical adoption is also being accelerated by national genomics programs, companion diagnostics recommendations, and public and private investments in laboratory infrastructure. High test prices, disjointed regulatory procedures, and a lack of qualified bioinformaticians and molecular technologists, particularly in lower-income regions, continue to be major participants are establishing strategic alliances, increasing locally produced goods, and putting in place training initiatives to develop technological know-how in order to overcome these obstacles. Automated high-throughput platforms are being implemented in the meanwhile to expedite processes and shorten turnaround times. In the future, the combination of AI-powered bioinformatics, increased reimbursement coverage, and more robust data-security frameworks will be essential for promoting long-term industry expansion. By providing more individualised, efficient cancer treatment in a variety of healthcare settings, the APAC molecular oncology diagnostics market is anticipated to take a sizable chunk of the worldwide precision oncology market by 2030. Key Attributes: Report Attribute Details No. of Pages 80 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $513.6 Million Forecasted Market Value (USD) by 2033 $1542 Million Compound Annual Growth Rate 12.9% Regions Covered Asia Pacific APAC Molecular Oncology Diagnostics Market Trends, Drivers & Challenges: Market Trends Technological Advancements: Rapid uptake of next generation sequencing (NGS), digital PCR and liquid biopsies (ctDNA/ctC) for non invasive, real time cancer monitoring. Consolidation & Partnerships: Increased M&A activity reshaping the competitive landscape, with major lab and diagnostics players acquiring or partnering on advanced platforms. Companion Diagnostics Integration: Growing adoption of CDx assays to match patients with targeted therapies, supported by evolving regulatory guidelines in key markets like Japan and Australia. Automation & High Throughput Platforms: Deployment of automated systems in both clinical and research labs to boost efficiency and sample throughput. Market Drivers Rising Cancer Incidence: Surging rates of breast, lung and colorectal cancers across China, India, Japan and Southeast Asia fueling demand for precise diagnostics. Precision Medicine Push: Strategic shift toward personalized oncology, with payers and providers investing in genotype-guided treatment pathways. Government & Public-Private Initiatives: National programs and partnerships underwriting infrastructure expansion, including genomics missions and companion diagnostics guidelines. Healthcare Infrastructure Investments: Capital inflows into lab upgrades, biotech R&D and specialized cancer centers enhancing regional capacity. Market Challenges High Cost of Testing: Advanced molecular assays remain expensive, limiting penetration in lower income APAC markets. Regulatory Complexity: Fragmented and evolving approval pathways across different countries delay product launches. Skilled Workforce Shortage: Insufficient numbers of trained molecular technologists and bioinformaticians impede broader clinical rollout. Data Security & Privacy: Handling of sensitive genomic and patient data raises compliance and cybersecurity concerns. Market Segmentation: Cancer Type Solid Tumors Hematologic Malignancies End User Hospitals and Diagnostic Centers Reference Laboratories Pharmaceutical and Biotechnology Companies Academic and Research Institutes Region Japan, China, India, South Korea, Australia, and Rest-of-Asia-Pacific For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Asia-Pacific Molecular Oncology Diagnostics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900